Introduction: Extended-release calcifediol (ERC) is an orally administered prohormone of active vitamin D (1,25-dihydroxyvitamin D [1,25D]) designed to safely and sufficiently increase serum total 25-hydroxyvitamin D (25D) to reduce elevated parathyroid hormone (PTH) in patients with non-dialysis-chronic kidney disease (ND-CKD). ERC is currently approved in the United States and Canada.Areas covered: Herein, key clinical data relating to the pharmacokinetics, pharmacodynamics, efficacy and safety of ERC are reviewed.Expert opinion: Currently available treatment options for secondary hyperparathyroidism (SHPT) in ND-CKD have limitations: the effectiveness of nutritional vitamin D supplements for reduction of PTH levels is unproven and active (1α-hydroxylated) vitamin D analogues elevate serum calcium, which increases the risk of hypercalcemia and vascular calcification. Clinical studies show that ERC is an effective, well tolerated treatment for SHPT in ND-CKD. ERC gradually raises serum 25D levels, resulting in physiologically regulated increases in serum 1,25D and sustained reductions in PTH, while avoiding clinically meaningful increases in serum phosphorus, calcium and fibroblast growth factor 23. ERC offers a new, effective and well tolerated treatment option for the early management of SHPT in patients with ND-CKD.
Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD) / M. Cozzolino, M. Ketteler. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 20:17(2019 Nov 22), pp. 2081-2093.
|Titolo:||Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD)|
COZZOLINO, MARIO GENNARO (Primo) (Corresponding)
|Parole Chiave:||25-hydroxyvitamin D; Chronic kidney disease; calcifediol; parathyroid hormone; secondary hyperparathyroidism; vitamin D deficiency; vitamin D insufficiency|
|Settore Scientifico Disciplinare:||Settore MED/14 - Nefrologia|
|Data di pubblicazione:||22-nov-2019|
|Data ahead of print / Data di stampa:||nov-2019|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1080/14656566.2019.1663826|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Evaluating extended release calcifediol as a treatment option for chronic kidney disease mineral and bone disorder CKD MBD.pdf||Publisher's version/PDF||Administrator Richiedi una copia|